SAN DIEGO, Nov. 18, 2010 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD ), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has released a report entitled: " A Platform to Address Bioterrorism." The report is available on the company's website at:
Or on SlideShare at:
About Aethlon MedicalAt Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity